Genenta Science and Anemocyte Launch Strategic Partnership for Off-the-Shelf LVV Plasmid DNA Production

Reuters
2025/10/24
Genenta Science and Anemocyte Launch Strategic Partnership for Off-the-Shelf LVV Plasmid DNA Production

Genenta Science S.p.A. has announced a strategic partnership with ANEMOCYTE to advance the production of off-the-shelf lentiviral vector (LVV) Plasmid DNA. Building on their existing collaboration, the new agreement will leverage Genenta's robust, clinically validated LVV Plasmid DNA technology platform-originating from the research of Professor Luigi Naldini-to enhance ANEMOCYTE's offerings for advanced therapy programs. This partnership aims to provide reliable, high-quality plasmid DNA materials from research and development to commercial stages, supporting the scalable development of advanced therapies across the life science industry.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genenta Science S.p.A. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001134718-en) on October 24, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10